Can an angiotensin receptor neprilysin inhibitor (ARNI) such as sacubitril/valsartan be used in a patient with unilateral renal artery stenosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can ARNI Be Used in Unilateral Renal Artery Stenosis?

ARNI (sacubitril/valsartan) can be used cautiously in unilateral renal artery stenosis with close monitoring of renal function, but it is not absolutely contraindicated. The key distinction is that unilateral stenosis carries lower risk than bilateral stenosis or stenosis in a solitary functioning kidney.

Guideline-Based Recommendations

The 2021 ACC Expert Consensus 1 explicitly lists renal artery stenosis as a "caution" rather than a contraindication for ARNI therapy. This is a critical distinction—cautions require careful monitoring and dose adjustment, while contraindications prohibit use entirely.

The FDA drug label 2 states that sacubitril/valsartan "may increase blood urea and serum creatinine levels in patients with bilateral or unilateral renal artery stenosis" and recommends monitoring renal function in these patients. Importantly, the label does not list unilateral renal artery stenosis as a contraindication.

Clinical Approach

When ARNI Can Be Considered:

  • Unilateral renal artery stenosis with a normally functioning contralateral kidney
  • Patient has heart failure with reduced ejection fraction requiring optimal medical therapy
  • Baseline renal function is stable (not severely impaired)
  • Close monitoring is feasible

Monitoring Requirements:

Monitor renal function closely 2:

  • Check serum creatinine and potassium within 1-2 weeks after initiation
  • Continue monitoring monthly for the first 3 months, then every 3 months 1
  • If eGFR decreases >30% or hyperkalemia develops, consider dose reduction 1

Contraindications (Do NOT Use):

  • Bilateral renal artery stenosis 3, 4
  • Stenosis in a solitary functioning kidney 5
  • Severe renal impairment (eGFR <30 mL/min/1.73 m²) requires dose reduction to 24/26 mg twice daily 1

Mechanistic Rationale

In unilateral stenosis, the contralateral normal kidney can compensate for reduced perfusion pressure to the stenotic kidney. The renin-angiotensin system blockade from ARNI primarily affects the stenotic kidney, but the normal kidney maintains overall renal function 6. However, there is theoretical concern about atrophy of the stenotic kidney over time 6.

Special Considerations

Revascularization may enable safer ARNI use: A 2024 case report 7 demonstrated that bilateral renal artery revascularization allowed safe reintroduction of ACE inhibitors and subsequent ARNI therapy in a patient with severe left ventricular dysfunction. This suggests that in selected patients with significant stenosis, addressing the anatomical problem first may optimize heart failure therapy.

Renal protection with ARNI: Multiple studies 8, 9, 10 demonstrate that sacubitril/valsartan may actually provide renal protection compared to ACE inhibitors or ARBs alone, slowing the decline in eGFR in heart failure patients. This benefit appears particularly pronounced in older patients and those with preserved ejection fraction 9.

Common Pitfalls to Avoid

  1. Do not confuse unilateral with bilateral stenosis—the risk profile is substantially different
  2. Do not skip baseline renal function assessment before initiating ARNI
  3. Do not fail to correct volume depletion before starting therapy, as this increases risk of acute kidney injury 2
  4. Do not use ARNI within 36 hours of ACE inhibitor due to angioedema risk 1, 11

References

Research

ACE inhibitors and unilateral renal artery stenosis--what price?

International journal of cardiology, 1996

Research

BOLD MRI to Evaluate the Effects of Sacubitril/Valsartan on Renal Protection in Type 2 Diabetics.

Diabetes, metabolic syndrome and obesity : targets and therapy, 2025

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.